Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US awards $132.5 million in vaccine contracts
GlaxoSmithKline has been awarded a contract for a value of at least $63.3 million. This contract is the latest to be awarded to the vaccine manufacturer and complements
GlaxoSmithKline has been awarded a contract for a value of at least $63.3 million. This contract is the latest to be awarded to the vaccine manufacturer and complements
The company said it intends to cooperate with the request. The subpoena seeks documents from 1999 to the present generally related to Endo’s knowledge of the use of
“This alliance is the fourth major partnership we have formed over the past six months and is consistent with our strategy to enable partners to leverage aptamers as
Topical ganciclovir has been available in Europe for the treatment of ocular viral infections for over 10 years. The product is currently marketed by Thea in Europe under
Xoma has received up-front payments for each of the additional collaboration programs and will also receive research funding for each project as well as success based milestones and
Geron scientists have described a newly discovered neurotrophic effect of the therapeutic GRNOPC1. In addition to the previously documented in vivo remyelinating activity of these cells, serves as
Tandemact is a combination of Actos and glimepiride HCl for type 2 diabetes. Takeda believes combining these medications may provide patients with an easier way for diabetes patients
Lialda is the first and only FDA-approved once-daily oral formulation of mesalamine. Shire will launch Lialda in the US in the first quarter of 2007. Once-daily Lialda with
Veno-occlusive disease (VOD) occurs when certain high dose chemotherapy and radiation therapies and stem cell transplantation damage cells of the blood vessels which results in a blockage of
The review period in Australia typically is 12 to 18 months from the date that the application is accepted. A marketing authorization application is also currently under review